281 related articles for article (PubMed ID: 17310826)
21. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand.
Koivusalo R; Krausz E; Ruotsalainen P; Helenius H; Hietanen S
Cancer Res; 2002 Dec; 62(24):7364-71. PubMed ID: 12499281
[TBL] [Abstract][Full Text] [Related]
22. [Reversal effect of antisense RNA targeting human papillomavirus 16 (HPV16) E6E7 on malignancy of human cervical cancer cell line SiHa].
Sima N; Wang W; Xu Q; Tian X; Luo AY; Lu YP; Wang SX; Ma D
Ai Zheng; 2007 Jan; 26(1):26-31. PubMed ID: 17222363
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs.
Koivusalo R; Krausz E; Helenius H; Hietanen S
Mol Pharmacol; 2005 Aug; 68(2):372-82. PubMed ID: 15908516
[TBL] [Abstract][Full Text] [Related]
24. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro.
Slebos RJ; Kessis TD; Chen AW; Han SM; Hedrick L; Cho KR
Virology; 1995 Apr; 208(1):111-20. PubMed ID: 11831691
[TBL] [Abstract][Full Text] [Related]
25. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.
Pim D; Massimi P; Banks L
Oncogene; 1997 Jul; 15(3):257-64. PubMed ID: 9233760
[TBL] [Abstract][Full Text] [Related]
26. Selective targeting of HPV-16 E6/E7 in cervical cancer cells with a potent oncolytic adenovirus and its enhanced effect with radiotherapy in vitro and vivo.
Wang W; Sima N; Kong D; Luo A; Gao Q; Liao S; Li W; Han L; Wang J; Wang S; Lu Y; Wang D; Xu G; Zhou J; Meng L; Ma D
Cancer Lett; 2010 May; 291(1):67-75. PubMed ID: 19903581
[TBL] [Abstract][Full Text] [Related]
27. HPV 16-E6-mediated degradation of intrinsic p53 is compensated by upregulation of p53 gene expression in normal cervical keratinocytes.
Kawamata Y; Mitsuhashi A; Unno Y; Kado S; Shino Y; Uesugi K; Eguchi O; Ishii J; Seki K; Sekiya S; Shirasawa H
Int J Oncol; 2002 Sep; 21(3):561-7. PubMed ID: 12168100
[TBL] [Abstract][Full Text] [Related]
28. The role of the E6-p53 interaction in the molecular pathogenesis of HPV.
Thomas M; Pim D; Banks L
Oncogene; 1999 Dec; 18(53):7690-700. PubMed ID: 10618709
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes.
Gu W; Putral L; Hengst K; Minto K; Saunders NA; Leggatt G; McMillan NA
Cancer Gene Ther; 2006 Nov; 13(11):1023-32. PubMed ID: 16810314
[TBL] [Abstract][Full Text] [Related]
30. The pro-angiogenic factors stimulated by human papillomavirus type 16 E6 and E7 protein in C33A and human fibroblasts.
Xi L; Wang S; Wang C; Xu Q; Li P; Tian X; Wu P; Wang W; Deng D; Zhou J; Ma D
Oncol Rep; 2009 Jan; 21(1):25-31. PubMed ID: 19082439
[TBL] [Abstract][Full Text] [Related]
31. Activities of human papillomavirus 16 E6 natural variants in human keratinocytes.
Asadurian Y; Kurilin H; Lichtig H; Jackman A; Gonen P; Tommasino M; Zehbe I; Sherman L
J Med Virol; 2007 Nov; 79(11):1751-60. PubMed ID: 17854024
[TBL] [Abstract][Full Text] [Related]
32. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation.
Thomas M; Matlashewski G; Pim D; Banks L
Oncogene; 1996 Jul; 13(2):265-73. PubMed ID: 8710365
[TBL] [Abstract][Full Text] [Related]
33. Role of p53 in antioxidant defense of HPV-positive cervical carcinoma cells following H2O2 exposure.
Ding B; Chi SG; Kim SH; Kang S; Cho JH; Kim DS; Cho NH
J Cell Sci; 2007 Jul; 120(Pt 13):2284-94. PubMed ID: 17567683
[TBL] [Abstract][Full Text] [Related]
34. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange.
Subbaramaiah K; Dannenberg AJ
Cancer Res; 2007 Apr; 67(8):3976-85. PubMed ID: 17440114
[TBL] [Abstract][Full Text] [Related]
35. Co-localization of the tumor-suppressor protein p53 and human papillomavirus E6 protein in human cervical carcinoma cell lines.
Liang XH; Volkmann M; Klein R; Herman B; Lockett SJ
Oncogene; 1993 Oct; 8(10):2645-52. PubMed ID: 8397367
[TBL] [Abstract][Full Text] [Related]
36. Ribozyme targeted on HPV16E6 mRNA induced apoptosis on human cervical carcinoma CaSKi cells.
Zheng YF; Zhang JR
Ai Zheng; 2003 May; 22(5):458-62. PubMed ID: 12753702
[TBL] [Abstract][Full Text] [Related]
37. Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blocks the E6-mediated degradation of cellular p53.
Giovane C; Trave G; Briones A; Lutz Y; Wasylyk B; Weiss E
J Mol Recognit; 1999; 12(2):141-52. PubMed ID: 10398405
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of serum- and calcium-induced terminal differentiation of human keratinocytes by HPV 16 E6: study of the association with p53 degradation, inhibition of p53 transactivation, and binding to E6BP.
Sherman L; Itzhaki H; Jackman A; Chen JJ; Koval D; Schlegel R
Virology; 2002 Jan; 292(2):309-20. PubMed ID: 11878933
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of radiation-induced apoptosis by dexamethasone in cervical carcinoma cell lines depends upon increased HPV E6/E7.
Kamradt MC; Mohideen N; Krueger E; Walter S; Vaughan AT
Br J Cancer; 2000 May; 82(10):1709-16. PubMed ID: 10817508
[TBL] [Abstract][Full Text] [Related]
40. [Inhibition of HPV16 E6 oncogene in cervical cancer by RNA interference].
Niu XY; Peng ZL; Duan WQ; Wang H; Chen YY; Fan YJ; Cheng YF; Qian XL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jan; 37(1):14-8. PubMed ID: 16468632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
